Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
Anand Padmanabhan, Professor and Clinician-Investigator at Mayo Clinic, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“We are pleased to publish this paper on VITT as part of a multi-institutional effort.
Some key findings include:
- Rare patients may have antibodies with kappa light chains. This contrasts with current thinking that VITT antibodies can only include lambda light chains. More to come!
- While VITT anti-PF4 antibodies are clonally restricted, the monoclone/oligoclones are not evident upon study of the entire IgG repertoire, and require anti-PF4 antibody isolation to appreciate clonal restriction. This is in contrast to MGTS where a monoclonal antibody is clearly seen by SPEP/IFE/Mass-Fix.
- In one patient, we noted persisting platelet activating antibodies 4 yrs after the acute event, with chronic low-grade thrombocytopenia. Long-term follow up may be important in VITT!
Congrats to the entire team!”
Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan
Read the Full Article on JTH

More posts featuring Anand Padmanabhan on Hemostasis Today.
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator
-
Aug 24, 2026, 15:15Jim Hoffman: Could Targeting NETosis Reduce Long-Term Risk After STEMI?
-
Aug 24, 2026, 14:58Danny Hsu: Rethinking Bleeding Risk in Patients on Anticoagulation